von Willebrand Factor in CHD and stroke: relationships and therapeutic implications

Marie-Therese Cooney1, Alexandra L Dudina, Patrick O'Callaghan

  • 1Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.

Insights

Elevated von Willebrand factor (vWF) levels are inconsistently linked to cardiovascular disease (CVD) and stroke risk. While vWF may predict outcomes in acute conditions, current evidence doesn't support its use in routine risk assessment.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Neurology

Background:

  • Atherosclerotic cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is a leading global cause of death.
  • Acute thrombotic arterial occlusion often precipitates fatal events in CVD.
  • Hematologic disorders, including coagulopathies, can precipitate ischemic stroke, particularly in younger individuals.

Purpose of the Study:

  • To investigate the pathophysiologic implications of elevated von Willebrand factor (vWF) levels in relation to CVD and cerebrovascular disease.
  • To clarify the role of vWF in the pathogenesis of atherosclerosis, CHD, and stroke.
  • To assess the utility of vWF measurement in predicting cardiovascular and cerebrovascular events.

Main Methods:

  • Review of existing literature on von Willebrand factor (vWF) and its association with cardiovascular disease (CVD) and stroke.
  • Analysis of studies investigating the relationship between elevated vWF levels and risk of coronary heart disease (CHD) and ischemic stroke.
  • Evaluation of vWF's predictive value for outcomes in acute coronary syndromes (ACS) and stroke.

Main Results:

  • Elevated vWF levels show variable and often inconsistent associations with CHD risk; causal criteria are not fully met.
  • The relationship between vWF levels and stroke risk is less established.
  • vWF measurement offers minimal additional predictive value for CVD risk beyond established factors like age, sex, cholesterol, and hypertension.
  • vWF may be more relevant for predicting outcomes in acute coronary syndromes (ACS) and stroke.

Conclusions:

  • The role of elevated von Willebrand factor (vWF) in the pathogenesis of atherosclerotic cardiovascular disease (CVD) and stroke remains poorly defined.
  • Current evidence does not strongly support using vWF levels for routine CVD or stroke risk prediction.
  • Further investigation is needed to determine if vWF levels can guide treatment decisions for acute coronary syndromes (ACS) or stroke.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...